CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Verapamil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02372253
NCT02372253Phase 2Completed

Repurposing of Verapamil as a Beta Cell Survival Therapy in Type 1 Diabetes

University of Alabama at Birmingham·interventional·Posted Feb 26, 2015·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating Verapamil and Placebo for Type 1 Diabetes Mellitus. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin production. The objectives are therefore to assess parameters of beta cell survival (including new biomarkers), insulin production and glucose control and the feasibility of this approach and thereby provide the basis for future, larger/expanded, longer-term verapamil studies and the off-label use of this approved drug for Type 1 Diabetes (T1D).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 26, 2015
Enrollment StartFeb 1, 2015
Primary CompletionDec 1, 2017
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.3 years ago

Interventions

Verapamildrug

Placebodrug